SEC Form 4 · accession 0000899243-18-002038
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul Bolno
Officer — See Remarks · Director
Period of report
Jan 23, 2018
Accepted (ET)
Jan 25, 2018 · 8:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 23, 2018 | A | 54,500 | $0.00 | A | 281,656 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (right to buy)F2 | $40.05 | Jan 23, 2018 | A | 109,000 | A | — | Jan 23, 2028 | Ordinary Shares | 109,000 | 109,000 | D |
Explanation of responses
- F1Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2019, through February 15, 2022.
- F2The option vests as to 25% of the shares on February 15, 2019 and vests as to an additional 6.25 of the shares quarterly thereafter until February 15, 2022.
Remarks
President and Chief Executive Officer